A physician reported via a sales representative that an (b)(6) year old male received deflux (dextranomer microspheres/hyaluronic acid) injection into the submucosa of the urinary bladder as treatment for vesicoureteral reflux.Additional medical history and concomitant medications were not provided.On (b)(6) 2014, the patient received deflux via the double-hit technique, injecting 1.8 cc into the right ureteral orifice.On an unknown date, the patient experienced ureterovesical junction obstruction.On (b)(6) 2014, stent placement was performed to correct the obstruction.At the time of this report, the patient remained in the hospital with the event improved, but still present.Causality was not provided.The company felt the event was possibly related to deflux.
|